Medlitics

AI-powered chronic disease management platform for patients, clinicians, hospitals, and insurers in Africa.

Cover Block

Publicly reported

Field	Value
Name	Medlitics
Tagline	AI-powered chronic disease management platform for patients, clinicians, hospitals, and insurers in Africa.
Headquarters	Wexford, Pennsylvania
Founded	2017
Stage	Pre-Seed
Business Model	B2B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Sub-Saharan Africa
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed

Summary and Signal

PUBLIC Medlitics is a Nigerian-founded digital health startup building an AI-enabled chronic disease management platform for patients, clinicians, hospitals, and insurers, and it merits investor attention because it is trying to address diabetes and hypertension with a connected care workflow tailored to African healthcare delivery constraints [BusinessDay, October 2026] [Punch, June 2026] [ThisDay, June 2026]. Public reporting places the company’s launch in 2026, while the structured company profile lists a 2017 founding and Wexford, Pennsylvania headquarters, which suggests investors should separate incorporation history from commercial launch timing as diligence begins [BusinessDay, October 2026] [Medlitics] [LinkedIn].

The product claim is broader than a single patient app: Medlitics says it combines AI, remote monitoring, digital health records, practitioner workflows, insurer connectivity, and an in-app wallet, with readings from wearables and connected medical devices reviewed every 15 minutes and alerts routed when patient values breach custom thresholds [Punch, June 2026] [The Sun Nigeria, June 2026] [Medlitics]. That multi-sided design is the main point of differentiation in the current evidence set, although nearly all functional and traction disclosures remain company-originated rather than independently verified [BusinessDay, October 2026] [Medlitics] [ThisDay, August 2026].

Leadership appears concentrated around founder and CEO Michael Fasere, who publicly describes prior work across technology, cybersecurity, and startup building, and whose LinkedIn profile ties him to Medlitics, 1App Technologies, and studies at Southern Methodist University’s Cox School of Business [LinkedIn] [Michael Fasere, March 2026]. The available public record also points to a clinical operator in Chief Nursing Officer Omowaleola Ashaye, but it does not yet provide a fully corroborated broader executive bench [Michael Fasere, March 2026].

On financing, the clearest public signal is not a completed round but a founder-stated $1 million pre-seed raise target disclosed in March 2026; no confirmed institutional investor, lead, or closed amount surfaced in the cited materials [Michael Fasere, March 2026]. The commercial model also needs clarification: Medlitics has publicly presented both a free patient and doctor product and a pricing page with Free, Basic at $9.99 per month, and Premium at $19.99 per month, which may reflect a freemium structure but is not yet fully reconciled in public reporting [Michael Fasere, March 2026] [Medlitics].

Over the next 12 to 18 months, the questions that matter are straightforward: whether reported adoption can convert from waitlist interest into durable clinical usage, whether hospital and insurer integrations move from product claims into named deployments, and whether the company can close external financing on terms that support expansion without outrunning proof points [BusinessDay, October 2026] [Medlitics] [Michael Fasere, March 2026]. The early signal is interesting, particularly the reported network of more than 800 verified doctors and more than 2,400 people on the waitlist, but those figures should be treated as company claims repeated in press coverage until independently corroborated [BusinessDay, October 2026] [The Sun Nigeria, June 2026].

No independent source found -- This section relies heavily on company statements and publisher repetition of company-reported claims, with limited independent corroboration beyond launch coverage and LinkedIn.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Sub-Saharan Africa
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed

Company Overview

PUBLIC Medlitics presents as an early-stage chronic care software company with a cross-border posture that is more specific in market focus than in corporate disclosure. On its website, the company describes itself as an AI-powered chronic disease management platform serving patients, clinicians, hospitals, and insurers, with product surfaces for users, practitioners, hospitals and clinics, and insurers [Medlitics]. The structured company profile lists headquarters in Wexford, Pennsylvania and a 2017 founding year, but the public materials surfaced here do not provide a state filing or a fuller legal-entity description to corroborate those points independently [Medlitics].

The public timeline is thin, which matters because founding year and launch year are doing different work in the story. The website indicates a multi-surface care platform with pricing now live, while contemporaneous company coverage in 2026 framed Medlitics as newly launching its chronic disease management product across Africa; for this section, the observable website presence is enough to establish an active public-facing company, but not enough to fill in intermediate milestones between incorporation, product development, and launch [Medlitics] [Medlitics, Pricing]. Michael Fasere is presented in the available materials as founder and CEO, and the company narrative centers on continuous management of diabetes and hypertension rather than episodic clinic visits [Medlitics].

No independent source found -- This section relies primarily on company website materials, with no corroborating state filing surfaced and no Crunchbase record provided in the source set.

The Product and the Stack

MIXED

The product pitch is straightforward: Medlitics is trying to make chronic care continuous rather than episodic, with one platform spanning patients, clinicians, hospitals, and insurers [BusinessDay, October 2026] [ThisDay, June 2026] [Medlitics]. Public descriptions consistently point to four core elements, AI-assisted monitoring, digital health records, connected care workflows, and insurer connectivity, with diabetes and hypertension named as the initial use cases [Punch, June 2026] [ThisDay, August 2026] [Medlitics]. The company website also describes separate surfaces for users, practitioners, hospitals and clinics, and insurers, including an app or portal for patients, a clinical workspace for practitioners, EHR integration for provider organizations, and an insurer portal with partner API access [Medlitics].

The operating logic, as publicly described, rests on remote data capture and threshold-based alerts. Punch reported in June 2026 that Medlitics collects readings from wearables and connected medical devices, checks those readings every 15 minutes, and alerts patients and clinicians when values move outside customized ranges [Punch, June 2026]. That is directionally useful for diabetes and hypertension management, but the public record does not yet show a verified demo, named device integrations, or independent technical documentation on model performance, sensitivity, or clinical outcomes, so the AI layer should be treated as a product claim rather than a validated technical advantage [Punch, June 2026] [ThisDay, August 2026].

Monetization appears early and somewhat mixed in the public record. The Medlitics pricing page lists a Free tier, a Basic plan at $9.99 per month, a Premium plan at $19.99 per month, and a 30-day Basic trial [Medlitics, Pricing], while founder-linked summaries and press coverage have also said the patient and doctor product is free, apparently to support adoption [Michael Fasere, March 2026] [BusinessDay, October 2026]. Separately, The Sun Nigeria reported that the platform includes an in-app wallet with multi-currency support and access to health-insurance products through partner networks, which suggests the company is testing both subscription and embedded-finance or distribution features from the outset [The Sun Nigeria, June 2026].

No independent source found -- This section relies mainly on company materials and publisher repetition of company claims, with partial corroboration from Punch, ThisDay, BusinessDay, and The Sun Nigeria.

The Market They Are Entering

PUBLIC

This market matters now because chronic disease is colliding with uneven care access, and digital coordination tools are starting to look less optional in African health systems that still manage too much of diabetes and hypertension episodically rather than continuously [BusinessDay, October 2026] [ThisDay, June 2026].

The evidence base here is thinner than investors would usually want for a sizing exercise. No named third-party market report in the supplied materials gives a direct TAM, SAM, or SOM for Medlitics’ addressable market, so the public record supports a qualitative read rather than a hard market model. What is visible is the company’s chosen wedge: chronic disease management, initially diabetes and hypertension, delivered through a platform that connects patients, clinicians, hospitals, and insurers [Punch, June 2026] [BusinessDay, October 2026] [Medlitics]. That framing places Medlitics at the intersection of several adjacent markets rather than neatly inside one category: digital therapeutics, remote patient monitoring, ambulatory care software, health records infrastructure, and insurance-enabled care coordination [ThisDay, August 2026] [The Sun Nigeria, June 2026] [Medlitics].

Demand drivers are easier to document than market size. Across the cited coverage, the recurring problem statement is cost and continuity: diabetes and hypertension require repeated monitoring, medication adherence, and earlier intervention, yet much of care delivery still happens around clinic visits and after deterioration [BusinessDay, October 2026] [ThisDay, June 2026]. Medlitics’ product design, collecting wearable and connected-device data, checking readings every 15 minutes, and alerting patients and clinicians when values move outside customized thresholds, is clearly aimed at that gap [Punch, June 2026]. If that workflow works in practice, the purchase logic is straightforward: providers get a monitoring layer, patients get more frequent feedback, and insurers get a chance to support lower-cost intervention earlier in the care cycle [BusinessDay, October 2026] [The Sun Nigeria, June 2026].

A second tailwind is the market’s multi-sided structure. Medlitics is not pitching only a patient app. Public materials describe separate surfaces for users, practitioners, hospitals and clinics, and insurers, alongside digital records, partner APIs, and an in-app wallet with multi-currency support and insurance access through partner networks [Medlitics] [The Sun Nigeria, June 2026]. That matters because in African health systems, the buyer and the user often differ. A patient may touch the app, but the commercial rationale may sit with a clinic seeking follow-up capacity, a hospital seeking longitudinal visibility, or an insurer looking for better member engagement and claims control. The same structure also raises execution difficulty, since multi-sided healthcare products usually need coordinated adoption rather than single-user virality.

The most relevant adjacent and substitute markets are conventional outpatient chronic-care management, point solutions for telemedicine, standalone electronic records, and consumer wellness apps. Public reporting suggests Medlitics is trying to compress several of those functions into one workflow: monitoring, records, care coordination, provider access, and insurance connectivity [ThisDay, August 2026] [Medlitics] [BusinessDay, October 2026]. The substitute risk is that hospitals may prefer narrower vendors that solve one operational problem well, while patients may default to lower-friction messaging, pharmacy, or device-specific apps. The counterpoint is that chronic disease management is one of the few healthtech categories where integrated workflow can be a feature rather than bloat, because readings, clinician action, payment, and adherence are tightly linked.

Macro and regulatory conditions cut both ways. The public sources point to affordability and access as central design constraints, which helps explain the company’s free entry tier for some users and its attempt to bridge providers and insurers in one system [Medlitics, Pricing] [The Sun Nigeria, June 2026]. But healthcare software that touches records, monitoring data, clinician workflows, and insurance relationships typically faces a higher implementation bar than consumer health products do. None of the supplied sources establish specific regulatory approvals, named health-system contracts, or country-by-country compliance milestones, so investors should read the opportunity as large in need terms but still early in commercialization proof [BusinessDay, October 2026] [ThisDay, June 2026].

Market lens	What the public evidence supports	Source basis
Core wedge	Chronic disease management, initially diabetes and hypertension	[Punch, June 2026] [BusinessDay, October 2026]
Buyer set	Patients, clinicians, hospitals, and insurers in one ecosystem	[BusinessDay, October 2026] [Medlitics]
Adjacent markets	Remote patient monitoring, digital records, connected care, insurance-linked care coordination	[ThisDay, August 2026] [The Sun Nigeria, June 2026] [Medlitics]
Demand signal	Company-reported waitlist growth and clinician interest, but not independently audited	[Michael Fasere, March 2026] [BusinessDay, October 2026]

The table shows a market defined more by workflow breadth than by a published category size. For now, the investable question is less the top-down market number and more whether a chronic-care platform can convert that broad need into repeatable provider, hospital, or insurer adoption.

No independent source found -- This section relies mainly on company materials and publisher coverage repeating company claims, with no named third-party market-sizing report or independently verified commercial deployment evidence in the supplied sources.

The Competitive Field

MIXED Medlitics appears to be positioning itself less as a single-point monitoring app and more as a connective layer across chronic-care workflows, but the public record still shows a category taking shape faster than a clearly bounded peer set [BusinessDay, October 2026] [Punch, June 2026] [Medlitics].

The competitive map is easiest to read in segments rather than by direct one-to-one rivals. In chronic disease management, Medlitics is competing first with offline care pathways, hospital outpatient follow-up, and fragmented WhatsApp or phone-based patient monitoring that remain common substitutes across African markets, even if they are not venture-backed products [ThisDay, June 2026] [ThisDay, August 2026]. In provider software, it also overlaps with electronic health record vendors and clinic workflow tools to the extent that Medlitics offers practitioner workspaces and hospital portals, while in insurance distribution it edges into health-financing and partner-network products through its wallet and insurance-access features [Medlitics] [The Sun Nigeria, June 2026].

That breadth is interesting, but it cuts both ways. A platform that spans patients, clinicians, hospitals, and insurers can create switching costs if the integrations, records, and monitoring data become operationally useful in one place [BusinessDay, October 2026] [Medlitics]. The same breadth can also slow execution because each buyer has a different sales cycle, compliance burden, and proof threshold, and the current public evidence does not yet show named hospital systems, insurers, or enterprise contracts that would confirm a lead in any one segment [BusinessDay, October 2026] [Michael Fasere, March 2026].

Where Medlitics has a visible edge today is in product ambition matched to a real regional care gap. Public materials describe continuous monitoring for diabetes and hypertension, data ingestion from wearables and connected devices, and clinician alerts based on customized thresholds, which is a more integrated proposition than a basic telemedicine front end or a stand-alone records tool [Punch, June 2026] [Medlitics]. If the reported network of more than 800 verified doctors and more than 2,400 waitlist users proves durable in production, that would matter because clinician availability and patient engagement are difficult to assemble at low cost in fragmented health systems [BusinessDay, October 2026] [The Sun Nigeria, June 2026].

The question is whether that edge is durable or perishable. Right now it looks perishable, because the strongest public traction points are company-reported and the capital base is not yet confirmed beyond a founder-stated $1 million pre-seed target [Michael Fasere, March 2026] [BusinessDay, October 2026]. In practical terms, product scope without confirmed distribution can be copied by better-capitalized clinic software vendors, insurer-backed care managers, or telehealth services that already control patient acquisition or reimbursement flows.

The company is most exposed where it does not own the channel. Hospitals own clinical workflow, insurers own payment approval and member access, and device makers or consumer health apps can own the upstream data relationship; Medlitics sits between all three and therefore needs partners to make the full model work [Medlitics] [The Sun Nigeria, June 2026]. That makes adjacent substitutes more immediate competitive pressure than a named startup peer in the current source set, particularly if providers decide a lighter integration or a single-purpose monitoring workflow is sufficient.

Over the next 18 months, the most plausible competitive scenario is bifurcation between broad platforms and narrow workflow products. Medlitics is the likely winner if chronic-care buyers in African markets increasingly want one vendor that can combine patient monitoring, practitioner workflows, records, and insurance connectivity in a single operating layer, and if the company can convert reported clinician and patient interest into named institutional deployments [BusinessDay, October 2026] [Medlitics]. Medlitics is also the likely loser if hospitals and insurers continue to prefer incumbent point solutions, or if reimbursement and partnership complexity forces the company to narrow before it has the capital to support a multi-sided rollout [Michael Fasere, March 2026] [ThisDay, August 2026].

Opportunity

Upside case

PUBLIC The prize here is not a point solution for blood-pressure reminders, but a chance to become a cross-stakeholder operating layer for chronic care in African markets where care is fragmented, monitoring is intermittent, and payment is often detached from longitudinal outcomes [BusinessDay, October 2026] [Punch, June 2026] [ThisDay, June 2026].

The headline opportunity is straightforward. If Medlitics can keep patients, clinicians, hospitals, and insurers in the same workflow, it could become one of the few platforms in its market that sits across monitoring, records, care coordination, and financing rather than selling only one of those functions [BusinessDay, October 2026] [The Sun Nigeria, June 2026] [Medlitics]. That outcome is still early and company-led, but it is not purely aspirational because the public product surface already spans patient and practitioner portals, hospital and clinic integration claims, insurer access, and an in-app wallet, while external coverage consistently describes diabetes and hypertension as the initial wedge rather than the full ambition [Medlitics] [Medlitics, Pricing] [Punch, June 2026] [ThisDay, August 2026]. In practice, chronic care is a category where workflow breadth can matter more than novelty at the model layer, since the commercial value often accrues to whoever coordinates the record, the intervention, and the reimbursement event.

A reasonable way to think about scale is through a small set of distinct paths rather than one monolithic outcome. The evidence does not yet establish paid enterprise adoption, so the scenarios below are conditional. Even so, each rests on public signals that the company is already trying to solve for a multi-party system, not a single-user app [BusinessDay, October 2026] [Michael Fasere, March 2026].

Scenario	What happens	Catalyst	Why it's plausible
Chronic-care system of record	Medlitics becomes the default software layer for ongoing diabetes and hypertension management across clinics, practitioners, and patient populations in selected African markets	A named hospital, clinic group, or NGO deployment proves that remote monitoring plus shared records improves continuity of care [Michael Fasere, March 2026] [ThisDay, June 2026]	The product is already described as combining remote monitoring, digital health records, and connected care, which is the minimum architecture for a longitudinal chronic-care workflow [Punch, June 2026] [Medlitics]
Insurer-linked care coordination rail	The insurer portal and partner access features mature into a claims-adjacent distribution channel, making Medlitics the interface through which chronic patients receive monitoring, benefits, and referrals	Insurance partnerships move from stated intent to embedded distribution, with reimbursement or subsidized enrollment attached [The Sun Nigeria, June 2026] [Michael Fasere, March 2026]	Public materials already frame insurers as first-class participants in the ecosystem, and the wallet plus insurance-access features suggest the company is building toward payment-enabled engagement rather than stand-alone tracking [BusinessDay, October 2026] [The Sun Nigeria, June 2026]
Practitioner network flywheel	Medlitics uses clinician onboarding to create a trusted supply layer, then converts patient demand and data flow into repeat usage across care settings	The reported base of verified doctors becomes active utilization, producing faster response times and more reasons for patients to stay in-network [BusinessDay, October 2026]	The company reported more than 800 verified doctors and more than 2,400 waitlist users by June 2026, which, if engagement is real, is the starting geometry of a two-sided network rather than a pure consumer app [BusinessDay, October 2026] [The Sun Nigeria, June 2026]

The compounding logic depends on whether one participant class makes the product better for the others. More patients create more monitoring data and more reasons for clinicians to remain active; more clinicians make the patient proposition stronger because alerts can route to assigned practitioners; insurer access can lower out-of-pocket friction; and hospital integrations, if they move from product claim to deployment, can anchor the record inside existing care delivery [Punch, June 2026] [The Sun Nigeria, June 2026] [Medlitics]. The earliest public signs of that flywheel are still company-reported, but they are directionally relevant: a clinician waitlist of 50-plus in March 2026, followed by company-claimed thousands of active patients and more than 800 verified doctors in June 2026, suggests the team is at least attempting to build both sides in parallel rather than sequencing them too slowly [Michael Fasere, March 2026] [BusinessDay, October 2026]. If that pattern holds, each additional stakeholder could reduce acquisition cost for the next one, which is usually the difference between an interesting health app and durable infrastructure.

The size of the win is best framed cautiously because no external market-sizing dataset or public comparable was provided in the source set. On the evidence available, the upper-end outcome would be a strategically important chronic-care platform with value accruing from software subscriptions, insurer relationships, and transaction-adjacent services such as wallet usage or care coordination, if those models convert from product design into revenue [Medlitics, Pricing] [The Sun Nigeria, June 2026]. What that could be worth is therefore best stated qualitatively: if the insurer-linked or system-of-record scenarios play out across multiple markets, this could support venture-scale outcomes in digital health infrastructure (scenario, not a forecast). The limiting factor in public underwriting is not whether the problem is meaningful, but that the current proof points are still mostly company-originated and stop short of verified enterprise revenue, named deployments, or independently corroborated retention [BusinessDay, October 2026] [Michael Fasere, March 2026].

No independent source found -- This section relies heavily on company statements and company-repeated media coverage, with no independent public verification of funding closed, named customers, or enterprise revenue.

Sources